(Total Views: 208)
Posted On: 02/01/2023 4:24:53 PM
Post# of 104
NetworkNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Reappointment of Dr. Hector Alila to Establish Advisory Group
Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced that Dr. Hector Alila has rejoined its board of directors with the specific responsibility of building a technical advisory board. “We are pleased to welcome Hector back to our board. With our focus on new scientific and clinical programs, our immediate need is to build a top-tier team of technical advisors to review our R&D activities and scientific approaches,” said Dr. Glynn Wilson, board chairman. “Dr. Alila brings 30 years of experience in translating novel research into clinical programs and product opportunities. He was most recently at Esperance Pharmaceuticals where he guided the clinical development of novel targeted cancer therapeutics. With a Ph.D. in physiology and immunology, and a broad R&D background covering cancer, autoimmune disease, infectious diseases, and gene therapy, he will be pivotal in helping us establish an advisory group and moving Jupiter Wellness forward into clinical trials and working with the FDA.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, today announced that Dr. Hector Alila has rejoined its board of directors with the specific responsibility of building a technical advisory board. “We are pleased to welcome Hector back to our board. With our focus on new scientific and clinical programs, our immediate need is to build a top-tier team of technical advisors to review our R&D activities and scientific approaches,” said Dr. Glynn Wilson, board chairman. “Dr. Alila brings 30 years of experience in translating novel research into clinical programs and product opportunities. He was most recently at Esperance Pharmaceuticals where he guided the clinical development of novel targeted cancer therapeutics. With a Ph.D. in physiology and immunology, and a broad R&D background covering cancer, autoimmune disease, infectious diseases, and gene therapy, he will be pivotal in helping us establish an advisory group and moving Jupiter Wellness forward into clinical trials and working with the FDA.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
